The use of stem cells to treat hearing loss is an area of active biomedical research, with growing but still preliminary scientific evidence. Hearing loss—especially sensorineural hearing loss—often results from damage to the hair cells or supporting structures in the cochlea, which do not naturally regenerate in mammals. Stem cell therapy aims to restore hearing by generating new hair cells or supporting cells, potentially reversing or mitigating hearing impairment.

Preclinical studies in animal models have demonstrated that various types of stem cells (such as embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells) can differentiate into inner ear cell types and, in some cases, partially restore hearing function. Several early-phase clinical trials have been initiated to assess the safety and potential efficacy of stem cell-based treatments in humans, but as of 2024, there is not yet robust clinical evidence demonstrating consistent and significant hearing restoration in people using this approach.

Although the theoretical rationale is strong and preclinical data are promising, the translation to effective human therapy is still in its infancy. More rigorous, large-scale clinical studies are needed to determine safety, optimal methods, and real-world efficacy. Therefore, stem cells for hearing loss are supported by preliminary scientific evidence, justifying a moderate rating, but not yet considered a clinically validated therapy.